Sue Desmond-Hellmann | |
|---|---|
.jpg) | |
| Born | 1958 (age 65–66) Napa, California, U.S. |
| Education | University of Nevada, Reno (BS, MD) University of California, Berkeley (MPH) |
| External audio | |
|---|---|
 “Pandemic Perspectives: Interview with Sue Desmond-Hellmann”, May 14, 2020, Science History Institute. |
Sue Desmond-Hellmann is an American oncologist and biotechnology leader who served as the Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 to 2020. In March 2024 she was elected as a board member of OpenAI. She was previously Chancellor of the University of California, San Francisco (UCSF), the first woman to hold the position, and Arthur and Toni Rembe Rock Distinguished Professor, and before that president of product development at Genentech, where she played a role in the development of the first gene-targeted cancer drugs, Avastin and Herceptin.[1]
- ^ Garde, Damian (17 December 2013). "Genentech's ex-R&D boss takes the reins at the Gates Foundation". Questex LLC. Fierce Biotech.